Poor
Mostly Aligned
Patient Risk:
Moderate
Summary
Only a small portion of the provided statements can be verified against the supplied label excerpts (boxed warning/all-cause mortality is consistent). Many other claims (indications approval year, CABP indication, mechanism, excretion/hepatic metabolism, detailed hepatic impairment PK and dose-adjustment recommendations, and liver monitoring) are not supported or contradicted by the provided label excerpts, so overall alignment is poor.
Category Scores
Accurate Statements
Tigecycline boxed warning / WARNING: increased all-cause mortality (adjusted risk difference 0.6%, 95% CI 0.1–1.2) and cause not established; reserve for use when alternative treatments are not suitable.
Supported by provided label excerpts: Section 5.1 (all-cause mortality, adjusted risk difference 0.6% [95% CI 0.1, 1.2], cause not established, reserved use when alternatives not suitable) and Section 6.1 (pooled analysis reiteration). Boxed warning provided is consistent with 5.1/6.1.
Unsupported Statements
Tigecycline is approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI).
No label excerpt provided supporting approval year or that specific approval timing.
Tigecycline is approved by the FDA in 2005 for the treatment of community-acquired bacterial pneumonia (CABP).
No label excerpt provided supporting approval year or CABP indication timing/approval.
Tigecycline is a glycylcycline antibiotic.
No label excerpt provided supporting drug class statement.
Tigecycline works by inhibiting protein synthesis in bacteria.
No label excerpt provided supporting mechanism-of-action statement.
Tigecycline is primarily excreted unchanged in the feces.
No label excerpt provided supporting excretion route.
Tigecycline has minimal hepatic metabolism.
No label excerpt provided supporting hepatic metabolism description.
In patients with mild liver impairment (Child-Pugh score 5-6), tigecycline pharmacokinetics are similar to healthy volunteers.
No label excerpt provided supporting hepatic impairment PK results by Child-Pugh category.
In patients with moderate liver impairment (Child-Pugh score 7-9), tigecycline clearance is reduced.
No label excerpt provided supporting clearance change.
In patients with moderate liver impairment (Child-Pugh score 7-9), tigecycline exposure is increased.
No label excerpt provided supporting exposure change.
The manufacturer of tigecycline recommends no dose adjustment for patients with mild liver impairment.
No label excerpt provided supporting specific dose adjustment recommendations by Child-Pugh category.
The manufacturer of tigecycline recommends a 25% dose reduction for patients with moderate liver impairment.
No label excerpt provided supporting specific dose reduction percentage.
The manufacturer of tigecycline recommends a 50% dose reduction for patients with severe liver impairment.
No label excerpt provided supporting specific dose reduction percentage.
Regular monitoring of liver function is essential in patients treated with tigecycline, particularly those with pre-existing liver disease.
No label excerpt provided supporting monitoring frequency or statement that it is 'essential.'
Liver function tests should be performed regularly to detect signs of liver injury or impairment in patients treated with tigecycline.
No label excerpt provided supporting this monitoring recommendation.
Patients with liver impairment may require dose adjustments to ensure optimal efficacy and safety.
No label excerpt provided supporting this general statement about liver impairment dose adjustments.
The use of tigecycline in combination with other medications that affect liver function should be approached with caution.
No label excerpt provided addressing drug interactions or hepatic-concomitant caution.
Increased exposure to tigecycline in patients with liver impairment can lead to adverse effects such as liver injury or impairment.
No label excerpt provided linking exposure increases in hepatic impairment to liver injury risk.
Liver function can impact the pharmacokinetics of tigecycline.
No label excerpt provided supporting this general pharmacokinetic relationship.
Tigecycline can be used in patients with severe liver disease, but dose adjustments may be necessary.
No label excerpt provided supporting use in severe liver disease and dose adjustment requirement.
Contradictions
Low
AI Statement
Tigecycline is approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI).
Label Reference
Not contradicted by the provided excerpts.
Important Omissions
Details of contraindications, warnings/precautions beyond all-cause mortality (e.g., other boxed warning items, specific contraindication list, and other clinically relevant cautions) were not evaluated because they were not provided in the AI statements or label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The provided label-supported safety claim (increased all-cause mortality) is accurate, but many other potentially safety-relevant statements (hepatic impairment dose/PK/monitoring and other cautions) cannot be confirmed from the supplied label excerpts; inaccurate or unsupported dosing/monitoring guidance could increase patient risk if relied upon.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Most claims are unsupported by the supplied label excerpts; only the all-cause mortality boxed warning portion is clearly supported.
Suggested Improvement
Limit claims to what is present in the provided label excerpts (e.g., boxed warning/Section 5.1 and 6.1). For hepatic impairment PK and dose adjustments, use the exact label language and figures from the appropriate sections; otherwise mark them as not supported.